Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | ERN1 | O75460 | 5/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.38 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27651048 | 0.83 | TDP1 (0.57) | TDP1ERN1PTGER4PTPN1HSD17B10 | |
| SCHEMBL15653272 | 0.83 | TDP1 (0.57) | TDP1ERN1PTGER4PTPN1HSD17B10 | |
| SCHEMBL17429171 | 0.83 | ERN1 (0.53) | TDP1ERN1PTGER4PTPN1HSD17B10 | |
| SCHEMBL15813516 | 0.82 | TDP1 (0.55) | TDP1ERN1PTGER4PTPN1HSD17B10 | |
| SCHEMBL8170934 | 0.82 | TDP1 (0.41) | TDP1ERN1HPGDMAPTMEN1 | |
| SCHEMBL15652421 | 0.82 | TDP1 (0.55) | TDP1ERN1PTGER4PTPN1HSD17B10 | |
| SCHEMBL15652935 | 0.82 | TDP1 (0.55) | TDP1ERN1PTGER4PTPN1HSD17B10 | |
| SCHEMBL11822958 | 0.80 | TDP1 (0.53) | TDP1ERN1PTGER4PTPN1HSD17B10 | |
| SCHEMBL24182447 | 0.79 | TDP1 (0.52) | TDP1ERN1PTPN1MAPTMEN1 | |
| SCHEMBL24500618 | 0.79 | HPGD (0.57) | TDP1HSD17B10HPGDMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114853608-A | Synthetic method of [60] fullerene hydrogen derivative catalyzed by N-heterocyclic carbene | 河南师范大学 | 2022-08-05 | — | — | CN | claimed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-2785695-B1 | NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-06-17 | — | — | EP | disclosed |
| EP-3221304-B1 | NOVEL CARBOXYLIC ACID COMPOUNDS USEFUL FOR INHIBITING MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 | LILLY CO ELI (US) | 2019-07-24 | — | — | EP | disclosed |
| EP-2114906-B1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2014-08-06 | — | — | EP | disclosed |
| US-8604061-B2 | 2-aminooxazolines as TAAR1 ligands | HOFFMANN-LA ROCHE INC. (US) | 2013-12-10 | — | — | US | disclosed |
| CN-101600700-B | Novel 2-amino oxazolines as TAAR1 ligands for CNS disorders | HOFFMANN LA ROCHE | 2013-08-21 | — | — | CN | disclosed |
| US-20120196903-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | GALLEY GUIDO (DE) | 2012-08-02 | — | — | US | disclosed |
| US-20100120864-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | GALLEY GUIDO | 2010-05-13 | — | — | US | disclosed |
| CN-101600700-A | Novel 2-aminooxazolines as TAAR1 ligands for CNS disorders | HOFFMANN LA ROCHE (CH) | 2009-12-09 | — | — | CN | disclosed |
| EP-2114906-A1 | NOVEL 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS | F. Hoffmann-Roche AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-20080261920-A1 | 2-Aminooxazolines as TAAR1 ligands | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-23 | — | — | US | disclosed |
| WO-2008092785-A1 | NOVEL 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120864-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | TAAR1, TAAR5, NPY2R | TDP1 767/4885ERN1 3566/4885PTGER4 982/4885 |
| US-20120196903-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | TAAR1, TAAR5, NPY2R | TDP1 957/4885ERN1 3709/4885PTGER4 1082/4885 |
| US-20080261920-A1 | 2-Aminooxazolines as TAAR1 ligands | TAAR1, TAAR5, NPY2R | TDP1 767/4885ERN1 3566/4885PTGER4 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.